-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although several glucose-lowering drugs are currently used in diabetes treatment, none of them can stop or reverse the progression of the disease
Current therapies targeting beta cells have only a temporary positive effect on insulin secretion
Erwin Ilegems, first author of the new study and senior researcher at the Department of Molecular Medicine and Surgery, Karolinska Institutet, said: "In diabetics, beta cells are challenged to produce large amounts of insulin
Repurposing a cancer drug
HIF-1α (hypoxia-inducible factor-1α) regulates the response to hypoxia
In collaboration with the research group of Prof.
Since insulin production decreases during the development of diabetes, current therapeutic strategies focus on increasing beta-cell insulin production
long-term treatment of diabetes
Unlike other treatments, PX-478 can improve beta cell activity without increasing insulin secretion
"We now plan to further investigate the translatability of our findings, hopefully paving the way for future clinical trials," said Teresa Pereira, a researcher at the Department of Medical Cell Biology at Uppsala University
Science Translational Medicine
HIF-1alpha inhibitor PX-478 preserves pancreatic beta cell function in diabetes